Jennifer Morrison, PA
Physician Assistant · Newport News, VANPI 1043234818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,928 of the $21,989 with a category attached, or 86.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,008 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $9K from 27 others
What the payments were for
- Consulting fees$7804%
- Speaking & faculty fees$1,8208%
- Food & beverage$18,92886%
- Education$4612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 48 | $3,573 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 117 | $2,766 |
| AbbVie | 155 | $2,130 |
| Johnson & Johnson | 84 | $1,944 |
| Neurocrine Biosciences, Inc. | 82 | $1,403 |
| Otsuka America Pharmaceutical, Inc. | 69 | $1,332 |
| Supernus Pharmaceuticals, Inc. | 75 | $1,293 |
| Alkermes, Inc. | 52 | $1,063 |
| Teva Pharmaceuticals USA, Inc. | 53 | $1,000 |
| Lundbeck LLC | 42 | $735 |
| E.r. Squibb & Sons, L.L.C. | 24 | $569 |
| Vanda Pharmaceuticals Inc. | 28 | $557 |
| Ironshore Pharmaceuticals Inc. | 29 | $543 |
| Axsome Therapeutics, Inc. | 16 | $502 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $457 |
| Tris Pharma Inc | 18 | $334 |
| Sunovion Pharmaceuticals Inc. | 12 | $281 |
| Avanir Pharmaceuticals, Inc. | 10 | $248 |
| Noven Therapeutics, LLC | 15 | $217 |
| Collegium Pharmaceutical, Inc. | 10 | $216 |
| Merck | 9 | $145 |
| Biogen | 3 | $139 |
| Jazz Pharmaceuticals Inc. | 6 | $113 |
| Neos Therapeutics, LP | 8 | $112 |
| Bausch Health US, LLC | 4 | $80 |
| Almatica Pharma LLC | 5 | $77 |
| Harmony Biosciences LLC | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Validus Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,989 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 12 | $101,754 |
| VraylarCariprazine Hcl | 17 | $24,225 |
| Lisdexamfetamine Dimesylate | 11 | $3,579 |
| Aripiprazole | 13 | $2,666 |
| Vilazodone Hcl | 12 | $2,431 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 60 | $2,063 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $1,096 |
| Zolpidem Tartrate ErZolpidem Tartrate | 22 | $1,070 |
| Bupropion XlBupropion Hcl | 62 | $1,041 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $856 |
| Venlafaxine Hcl | 12 | $665 |
| Olanzapine | 14 | $582 |
| Duloxetine Hcl | 36 | $558 |
| Bupropion Hcl | 13 | $537 |
| Alprazolam | 54 | $488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,000 | $101,75412 claims |
| AbbVieVraylar | $2,130 | $24,22517 claims |
| Almatica Pharma LLCSertraline Hcl | $77 | $26328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Newport News
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
- Juliette BeristainVirginia Beach$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.